Previous studies have identified an association between the gene glyoxalase 1 (Glo1) and anxiety-like behavior in mice and have shown that the substrate of GLO1, methylglyoxal, is a competitive partial agonist at GABA A receptors. Given the well-established role of GABA A receptors in the behavioral effects of ethanol (EtOH), we investigated the role of Glo1 in voluntary EtOH consumption in mice using the drinking in the dark (DID) paradigm. Transgenic mice overexpressing Glo1 on both FVB/NJ (FVB) or C57BL/6J (B6) backgrounds showed increased voluntary EtOH consumption compared to their wild-type littermates in DID. Furthermore, transgenic Glo1 knockdown mice on a B6 background showed decreased voluntary EtOH consumption in DID. These genetic manipulations of Glo1 had no effect on sucrose, saccharin or water consumption. Finally, we found that a small molecule GLO1 inhibitor (S-bromobenzylglutathione cyclopentyl diester (pBBG; 6.25, 12.5 mg/kg)) reduced EtOH consumption compared to vehicle treated B6 mice without altering saccharin or water consumption. Sucrose consumption was only reduced by the higher (12.5 mg/kg) dose of pBBG. We did not observe differences in the loss of righting reflex (LORR) or EtOH-induced foot slips on the balance beam in response to acute EtOH administration (LORR: 4 g/kg, Balance Beam: 1.25 g/kg) in B6 or FVB mice overexpressing Glo1, nor in B6 mice treated with pBBG. These data are the first to implicate Glo1 in EtOH-related behaviors and suggest that GLO1 inhibitors may have therapeutic potential for the treatment of alcohol use disorders.
INTRODUCTION
Alcohol use disorders (AUD) are characterized by 'a problematic pattern of alcohol use leading to clinically significant impairment or distress' (DSM V). There are a dearth of pharmacological treatments for AUDs and those that exist are only modestly effective and may even be ineffective in certain individuals (Dawson, Goldstein and Grant, 2007; Maisel et al. 2012) . Further, AUDs share high comorbidity with several psychiatric disorders including generalized anxiety disorder (GAD) (Grant et al. 2004; Boschloo et al. 2011; Smith & Randall 2012) , and these comorbid disorders are associated with worse treatment outcomes (Driessen et al. 2001; Bruce et al. 2005; Smith & Book 2010) . Thus, identifying novel treatments for AUD, especially ones that might also address psychiatric co-morbidities, is of critical importance.
While it is impossible to fully recapitulate AUDs in model organisms, key aspects of AUD can be modeled and may be used to evaluate the potential effectiveness of novel therapeutic targets. Binge drinking is defined as drinking enough to obtain a blood alcohol concentration (BAC) of 0.08 g/dl or above (National Institute on Alcohol Abuse & Alcoholism 2004) . Binge drinking is a risk factor for the development of AUDs (Viner and Taylor 2007) and accounts for a large portion of harm that is associated with AUDs (Bouchery et al. 2011) . The drinking in the dark (DID) paradigm was developed to model binge drinking in rodents (Rhodes et al. 2005) . DID takes advantage of the tendency of mice to voluntarily consume large amounts of ethanol (EtOH) when it is presented for a limited period of time during the dark phase of the light cycle. Under these conditions several inbred mouse strains will freely consume enough EtOH to achieve BAC greater than 0.08 g/dl, and will thus demonstrate overt signs of behavioral intoxication (Rhodes et al. 2005 ). Importantly, current treatments for AUDs such as naltrexone and acamprosate reduce EtOH consumption in this model without altering water or sucrose consumption, illustrating the strong predictive validity of DID (Kamdar et al. 2007; Gupta et al. 2008) .
Several previous studies have identified an association between expression of the gene, glyoxalase 1 (Glo1) and anxiety-like behavior in mice (Hovatta et al. 2005; Williams et al. 2009; ). Glo1's protein product, GLO1, is a ubiquitous cytosolic enzyme that mediates the detoxification of methylglyoxal (MG), which is a non-enzymatic by-product of glycolysis (Thornalley 1996) . We previously showed that transgenic overexpression of Glo1 increased anxiety-like behavior and that direct administration of MG decreased anxiety-like behavior in mice. Further, a pharmacological inhibitor of GLO1, S-bromobenzylglutathione cyclopentyl diester (pBBG), increased MG concentrations in brain and reduced anxiety-like behavior. We subsequently determined that MG is a competitive partial agonist at GABA A receptors, likely explaining the effect of GLO1 on anxiety-like behavior .
Many of the behavioral effects associated with EtOH use are mediated through the actions of EtOH at GABA A receptors and modulation of GABA A receptor activation alters both the behavioral effects of EtOH and voluntary EtOH consumption (Grobin et al. 1998; Moore et al. 2007; Kumar et al. 2009; Liang & Olsen 2014) . Because GLO1 regulates the concentration of MG, which is a competitive partial agonist at GABA-A receptors, we hypothesized that increased Glo1 expression and corresponding decreases in MG would increase EtOH consumption, while reduced Glo1 expression or reduced enzymatic activity of GLO1, which would increase MG concentrations, would decrease EtOH consumption.
MATERIALS AND METHODS

Mice
Transgenic (TG) mice overexpressing Glo1 on either a FVB/NJ (FVB) or C57BL/6J (B6) background were generated by insertion of a BAC transgene, as previously described . FVB TGs used in this paper had approximately 35 copies of the transgene while B6 TGs had approximately eight copies; previously published estimates of brain mRNA suggest that these transgenes induced 17-fold (FVB) and 5-fold (B6) increases in brain Glo1 mRNA relative to wild-type (WT) littermates . Glo1 knock-down (KD) mice were generated on a C57BL/6 background in the lab of Dr. Michael Brownlee (Albert Einstein College of Medicine, Bronx, NY) and show an approximately 45-65 per cent reduction in GLO1 enzymatic activity as previously described (El-Osta et al. 2008) . KD mice have been maintained in our lab by continuing to backcross to B6 for more than five generations. In all studies of mutant mice, TG, KD and their corresponding WT littermates were tested at ages 10-16 weeks; both males and females were used. For studies using the GLO1 inhibitor (pBBG), male B6 mice were purchased from The Jackson Laboratory (JAX) and tested when they were 8-12 weeks old. All mice were group housed on a reverse light cycle (12/12 h light/dark, lights on at 22:30) for at least 2 weeks prior to testing. All mice were singly housed beginning exactly 5 days before the start of DID testing. All procedures were approved by the Institutional Animal Care and Use Committee at the University of Chicago and performed in accordance with the National Institute of Health Guidelines for the Care and Use of Laboratory Animals.
DID
Our studies were performed using the two day DID model of binge drinking as described in Rhodes et al. (2007) . Briefly, 3 hours into the dark cycle, mice were given access to 20 per cent EtOH (vol/vol) for 2 hours on day 1 and for 4 hours on day 2. The same animals were tested to determine their consumption of other solutions using the same 2-day DID paradigm. We examined 10 per cent sucrose (wt/vol), 0.2 per cent Saccharin (wt/vol) and water. Mice had at least 1 day of rest between studies. For example, in one week, sucrose testing took place on a Monday and Tuesday, the mice were undisturbed on Wednesday, then water testing took place Thursday and Friday. For studies using the GLO1 inhibitor pBBG, mice followed a similar testing schedule, but received injections of the inhibitor 2 hours prior to testing on day 2. This 2 hour time-point was used to allow time for accumulation of MG in the brain through a reduction in MG clearance; we have previously shown increases of MG in the brain and anxiolytic behaviors effects 2 hours after administration of pBBG Distler et al. 2013) . TG and KD mice underwent testing in the following order: sucrose, water, saccharin and EtOH. Mice receiving the GLO1 inhibitor pBBG underwent testing in a different order: sucrose, saccharin, water and EtOH. There was no particular reason for this difference. Blood samples were taken for BEC analysis immediately following the 4-hour exposure to EtOH on day 2 of DID.
Loss of righting reflex (LORR)
Separate cohorts of treatment naïve mice (FVB TG, B6 TG and their WT littermates or WT male B6 from JAX for pBBG studies) were used for the LORR studies. pBBG injections occurred 2 hours before mice received EtOH injections. LORR testing began with a 4 g/kg IP injection of EtOH; the injection consisted of a 20 per cent EtOH solution that was prepared by diluting a 95 per cent EtOH with 0.9 per cent saline. LORR was defined as the time at which a mouse could no longer right itself twice within 30 seconds. Mice taking longer than 3.5 minutes to lose their righting reflex were deemed to have received a misplaced injection and were excluded from analysis. Of 112 mice tested, 8 were excluded for either failing to lose their righting reflex (5 of 8) or for taking longer than 3.5 minutes to lose their righting reflex (3 of 8). Of the 8 that were excluded, 4 were FVB (1 TG, 3 WT) and 4 were B6 that were purchased from JAX for the pharmacological studies. No mice were excluded from the B6 Glo1 overexpressing line based on these criteria. Duration of LORR was defined as the time at which a mouse regained the ability to right itself 3 times in 60 seconds minus the time it achieved LORR.
Balance beam
Separate cohorts of treatment naïve mice (FVB TG, B6 TG and their corresponding WT littermates or WT male B6 from JAX for pBBG studies) were used for the balance beam study. The day before testing, mice were trained to traverse a balance beam (97 cm long, 16 mm wide, suspended 56 cm above the floor) by placing mice at one end of the balance beam and encouraging them, if necessary, to walk to the other side of the balance beam by a light nudge at the base of the tail using the eraser end of a pencil. Previous studies (Linsenbardt et al. 2011; Rhodes et al. 2007 ) have shown that this training is sufficient to have mice traverse the beam during testing without encouragement. FVB and B6 TG mice were tested on the balance beam over 2 days. On day 1 they received no injections and baseline foot slips were assessed. On day 2, all mice received 1.25 g/kg EtOH 10 minutes before being placed on the balance beam. In a separate study, we used a 3 × 2 experimental design to assess interactions between drug (VEH, MG or pBBG) and EtOH (saline or EtOH) on ataxia (foot slips). WT B6 JAX mice received injections of either VEH or 6.25 mg/kg pBBG 2 hours before testing and then received another injection of either saline, 50 mg/kg MG, 1.25 g/kgEtOH or 50 mg/kg MG + 1.25 g/kg EtOH 10 minutes before testing. Mice were then placed on one end of the balance beam and allowed to traverse to the other end while hind foot slips were recorded by an observer blind to treatment conditions.
EtOH metabolism
Novel sets of EtOH naïve mice (FVB TG, B6 TG, B6 KD and their corresponding WT littermates) were used to assess EtOH metabolism. A 2 g/kg dose of EtOH was administered IP using a 20 per cent EtOH solution that was prepared by diluting a 95 per cent stock solution with 0.9 per cent saline. Blood (20 μl) was taken from the tail at 15, 30, 60 and 120 minutes post injection and blood EtOH concentrations (BECs) were determined as described below.
BEC
Blood samples were processed by the laboratory of Professor John C. Crabbe at Oregon Health and Sciences University using procedures described previously (Barkley-Levenson & Crabbe 2012). For the DID study, 20-μl blood samples were taken immediately after the 4-hour EtOH exposure on day 2. For the EtOH metabolism study 20-μl blood samples were taken at the indicated time points. For the LORR study, 20-μl blood samples were taken upon the regain of the righting reflex. All samples were placed into microcentrifuge tubes containing 50-μl zinc sulfate on ice. Following collection of all blood samples, 50 μl of 0.3 N barium hydroxide and 300 μl distilled water were added and samples were centrifuged at 12 000 RPM for 5 minutes. The supernatant was then removed, placed in a sealed, air-tight container, frozen and subsequently analyzed by gas chromatography. Samples were compared to a standard EtOH concentration curve. Drugs S-bromobenzylglutathione cyclopentyl diester (pBBG) was synthesized in the laboratory of Professor Alexander Arnold at the University of Wisconsin Milwaukee as follows: In a dry glass vial, L-Glutathione (307 mg, 1 mmol) was dissolved in water (2 ml) at room temperature for 5 minutes. Two milliliters of 6 N NaOH was added slowly followed by the dropwise addition of a solution of 4-bromobenzyl bromide (1.1 mmol) in methanol (2 ml). The reaction mixture was stirred at room temperature for 3 hours. The product was precipitated by adding 6 N HCL (2 ml). The precipitate was washed with water and dried. The crude product was dissolved in cyclopentanol (10 ml). To the solution, few drops of concentrated sulfuric acid were added and stirred for 48 hours. The completion of the reaction was monitored by LC/MS until the disappearance of the starting material. The product was precipitated by adding hexanes. The precipitation step was repeated three times giving 122 mg (20 per cent yield). 
Statistical analysis
Data were analyzed using t-Test or ANOVA. Holm-Sidak multiple comparisons procedures were used to determine which doses yielded significantly different responses. p-Values less than 0.05 were considered significant.
RESULTS
TG mice on both FVB and B6 backgrounds showed significantly increased EtOH consumption over the 4 hours of drinking on day 2 compared to their WT littermates in DID (Fig. 1a-b ). Mice on a FVB background showed significant effects of genotype and sex ( Fig. 1a; F(1,30) = 4.643 p < 0.05, F(1,30) = 6.913; p < 0.05) with TGs drinking more EtOH than WTs and females drinking more than males. There was no significant interaction between genotype and sex (F(1,33) = 0.575 p > 0.05). Mice on a B6 background also showed a significant effect of genotype ( Fig. 1b; F (1,38) = 4.251; p < 0.05), but showed no significant effect of sex (F(1,41) = 2.26; p > 0.05) or interaction between genotype and sex (F(1,41) = 0.334; p > 0.05). Conversely, KD mice showed significantly reduced EtOH consumption (Fig. 1c) . There was a significant effect of both genotype and sex ( Fig. 1c ; F(1,45) = 4.633, p < 0.05; F(1,45) = 8.951, p < 0.01), with KDs drinking less EtOH than WTs and females drinking more than males. There was no significant interaction between genotype and sex (F(1,48) = 0.554; p > 0.05). BECs were positively correlated with EtOH consumption in all strains (FVB: R 2 = 0.3, p < 0.01; B6: R 2 = 0.2, p < 0.05; KD: R 2 = 0.2, p < 0.01). Importantly, genotype had no effect on water, sucrose or saccharin consumption (Fig. S1a-l Because Glo1 knockdown mice showed reduced EtOH consumption, we next investigated the therapeutic potential of GLO1 inhibition by using a pharmacological inhibitor of GLO1, pBBG . Male B6 WT mice received an IP injection of pBBG (0, 6.25 or 12.5 mg/kg) 2 hours before testing on day 2 of the DID paradigm. There was a significant effect of treatment on EtOH consumption ( Fig. 2a ; F(2,43) = 4.712; p < 0.05). Post hoc tests revealed that both doses significantly reduced EtOH consumption compared to vehicle treatment (p < 0.05). BECs were positively correlated with EtOH consumption (R 2 = 0.3, p < 0.001).
There was no effect of pBBG on water consumption ( Fig. 2b ; F(2,43) = 0.866 p > 0.05) or saccharin consumption ( Fig. 2c ; F(2,43) = 0.969 p > 0.05), but sucrose consumption was reduced following the 12.5 mg/kg dose of pBBG ( Fig. 2d ; Sucrose F(2, 41) = 8.354; p < 0.001; post hoc for 0 versus 12.5 mg/kg p < 0.002). However, the 6.25 mg/kg dose of pBBG did not change sucrose consumption. In a separate set of studies we found that there was a significant effect of treatment on EtOH consumption when using higher doses of pBBG ( Fig. S2a ; 25 mg/kg and 50 mg/kg; F(2,42) = 9.113; p < 0.001). However, these doses also changed consumption of water and sucrose, which confounds the interpretation of DID. Specifically, there was a significant main effect of treatment on water consumption (F(2,41) = 3.522; p < 0.05); post hoc tests were suggestive for both doses ( Fig. S2b ; 0 versus 25 mg/kg: p = 0.079; 0 versus 50 mg/kg: p = 0.053). There was a non-significant trend of treatment on saccharin consumption ( Fig. S2c ; F(2,43) = 3.05; p = 0.058) and a significant effect of treatment on sucrose consumption (Fig S2d; F(2,42) = 6.201; p < 0.01). For sucrose, post hoc tests were suggestive for 25 mg/kg pBBG (p = 0.064) and were significant for the 50 mg/kg pBBG (p < 0.05).
Finally, we performed the LORR and balance beam tests to determine whether manipulations of GLO1 altered sensitivity to the sedative or ataxic effects of EtOH. In LORR, we observed no significant differences in duration of LORR between TG Glo1 overexpressing and WT mice on either FVB ( Fig. 3a ; Genotype: F(1,19) = 1.458 p > 0.05; Sex: F(1,19) = 2.775 p > 0.05; Interaction F(1,19) = 0.0797 p > 0.05) or B6 backgrounds ( Fig. 3b ; Genotype F(1,25) = 0.15 p > 0.05; Sex F(1,25) = 0.203 p > 0.05; Interaction F(1,25) = 2.224 p > 0.05). Similarly, we did not observe a significant effect of treatment (VEH, 6.25 mg/kg or 12.5 mg/kg pBBG) on duration of LORR in male B6 WT mice ( Fig. 3c; F On the balance beam, mice overexpressing Glo1 (TG) showed no differences in foot slips at baseline or following EtOH injections on either an FVB background ( In WT male B6 mice, EtOH treatment significantly increased foot slips ( Fig.3f; F(1,68) = 84.479, p < 0.001), but there was no effect of drug treatment (VEH, 50 mg/kg MG or 6.25 mg/kg pBBG; F(2, 68) < 0.0001 p > 0.05) nor was there an interaction (F(2,68) = 0.501 p > 0.05). In a separate study in WT male B6 mice using a higher dose of pBBG (50 mg/kg), EtOH treatment significantly increased foot slips ( Fig. 3g; F(1,31) = 84.621, p < 0.001), but again, there was no effect of pBBG treatment (F(1,31) = 0.0168 p > 0.05) nor was there an interaction (F(1,31) = 0.42 p > 0.05). Figure 2 The GLO1 inhibitor pBBG reduces EtOH consumption. Acute IP injection (2 h before testing) with the indicated doses of pBBG reduces (a) EtOH consumption at multiple doses, but has no effect on (b) water or (c) 0.2 per cent saccharin consumption. (d) Sucrose consumption was reduced only at the 12.5 mg/kg dose. n = 14-15 per group for each test *p < 0.05, ** p < 0.01 comparisons to VEH
DISCUSSION
Our data demonstrate a novel role for GLO1 in the regulation of EtOH consumption. We observed increased EtOH consumption in FVB and B6 TG mice overexpressing Glo1. Conversely, we observed decreased EtOH consumption following both genetic knockdown of Glo1 (KD) and pharmacological inhibition of GLO1 by pBBG. To the best of our knowledge, these are the first studies to demonstrate that manipulations of Glo1 expression and enzymatic activity can alter voluntary EtOH consumption. These data suggest that pharmacological inhibition of GLO1 could be used to reduce voluntary EtOH consumption.
Importantly, neither overexpressing nor knocking down Glo1 affected general consummatory behavior as there was no effect on 10 per cent sucrose or water consumption. Additionally, genotype did not alter EtOH metabolism. While all doses of the GLO1 inhibitor (pBBG) reduced EtOH consumption, the higher doses altered consumption of sucrose (12.5, 25 and 50 mg/kg) and water (25, 50 mg/kg) consumption. No doses of pBBG altered saccharin consumption nor did genotype have an effect on saccharin consumption in TG mice. While there was a non-significant trend towards an effect of KD on 0.2 per cent saccharin consumption, the consistent effects of Glo1 manipulations on EtOH consumption and lack of general effect of Glo1 manipulation on other consummatory behaviors suggests that Glo1 manipulations are not leading to decreased EtOH drinking through changes in their tastant sensitivity. Additionally, the DID studies may be limited by effects from either repeated testing or Figure 3 EtOH induced LORR and balance beam foot slips are not altered in Glo1 TG overexpressing mice or in mice treated with MG or pBBG. Mice overexpressing Glo1 (TG) on an (a) FVB background (n = 9 WT, 13 TG), or (b) B6 background (n = 15 WT, 11 TG) show no differences in duration of LORR following a 4 g/kg EtOH injection. (c) WT male B6 mice treated with 0, 6.25 or 12.5 mg/kg pBBG 2 hours before EtOH injections showed no differences in duration of LORR (n = 19-20 per group). On the balance beam, mice overexpressing Glo1 (TG) showed no differences in foot slips at baseline or following 1.25 g/kg EtOH injections on either an (d) FVB background (n = 8 WT, 9 TG), or (e) B6 background (n = 8 WT, 9 TG). (f) In WT B6 mice (n = 11-12 per group) EtOH treatment significantly increased foot slips (p < 0.001), but there was no interaction between drug (VEH, 50 mg/kg MG or 6.25 mg/kg pBBG) and EtOH treatment (g). Using a higher dose of pBBG (50 mg/kg) in WT B6 mice (n = 8 per group), EtOH treatment significantly increased foot slips (p < 0.001), but again, there was no interaction between drug and EtOH treatment.
order of testing. However, this again seems unlikely given the complimentary and inverse effects of Glo1 overexpression versus Glo1 knockdown or GLO1 inhibition.
Correlations between EtOH drinking and BEC were somewhat modest, although they were not dissimilar to those seen by others (e.g. Wilcox et al. 2013 ) and may be a reflection of the extended access (4 hours) wherein mice will show different patterns of drinking. For example, Wilcox et al. (2013) showed that in DID mice may 'front-load' or drink EtOH at the highest rate during the first 15 minutes of EtOH access which could lead to high overall drinking, but lower than expected BECs at the end of the session.
In studies using Glo1 overexpressing mice or Glo1 knockdown, both males and females were used. We saw no interactions between sex and genotype in any of our measures. A limitation of the GLO1 inhibitor studies is that we did not use females. While the lack of female subjects in the inhibitor study makes it unclear whether the GLO1 inhibitor would reduce EtOH consumption in females, the effects seen in the transgenic animals suggest that EtOH consumption in females would respond to GLO1 inhibition.
We have previously shown that MG, which is metabolized by GLO1, is a competitive partial agonist at GABA A receptors McMurray et al. 2014) . We suspect that the changes in MG concentrations, which are caused by manipulations of Glo1 expression or enzymatic inhibition , modulate EtOH consumption via the action of MG at GABA A receptors. There is a well-established role of the GABA A receptor system in regulating EtOH consumption (Kumar et al. 2009 ). Indeed, GABAergic drugs such as muscimol and THIP reduce EtOH consumption as measured using DID, although they also reduce other consummatory behavior such as sucrose and water consumption (Moore et al. 2007 ). Additionally, a recent mouse study found that GABA A receptor-mediated signaling was depressed in the striatum following repeated EtOH consumption through 6 weeks of DID (Wilcox et al. 2013) . Our data are consistent with those supporting a role for GABA A receptors in the regulation of EtOH consumption in DID and show that these effects can be obtained via manipulation of Glo1.
It is possible that MG and GLO1 are involved in the normal regulation of alcohol consumption through the activity of MG at GABA A receptors. MG is an endogenously produced byproduct of glycolysis (Thornalley 1996) . However, MG is also found in almost all foods and in many alcoholic beverages (Nemet et al. 2006; Angeloni et al. 2014; Ojeda et al. 2014) . Whether concentrations of MG reach pharmacologically meaningful levels is unknown, but it raises the possibility that direct ingestion of MG may be an important component of the pharmacological properties of fermented beverages. MG may provide negative feedback on alcohol consumption whereby alcohol increases MG levels both through endogenous production and exogenous ingestion. High levels of MG may occupy GABA A receptors and lead to a reduction in EtOH consumption. This reduction may be the result of antagonistic-like properties of MG by reducing the maximal amplitude of GABAergic currents because of its actions as a partial agonist. This may be similar to decreased EtOH consumption seen after systemic administration GABA A antagonists (Koob et al. 1998; Chester & Cunningham 2002; Koob 2006) . Alternatively, increased activation from baseline could increase sensitivity to the hypnotic or ataxic effects of alcohol use and lead to early termination of drinking similar to the reduction in consumption others have seen using GABA A receptor agonists such as muscimol (Moore et al. 2007 ). However, this theory is not supported by our observation that there were no differences in LORR or footslips in either TG mice or mice treated with the GLO1 inhibitor.
The ability of GLO1 inhibitors to reduce EtOH consumption in DID suggest that GLO1 inhibitors may be a viable for the treatment of AUDs. We previously showed that GLO1 inhibitors reduce anxiety-like behavior in mice and have suggested that GLO1 inhibitors could be used for the treatment of anxiety disorders McMurray et al. 2014) , which are highly comorbid with AUDs (Smith and Randall 2012) . Current pharmacological treatments for anxiety disorders include selective serotonin reuptake inhibitors (e.g. fluoxetine), serotonin-norepinephrine reuptake inhibitors and benzodiazepines (e.g. diazepam) that are positive allosteric modulators that do not directly activate GABA A receptor (e.g. diazepam, a benzodiazepine) (Smith and Randall 2012) . Drugs most commonly used for the treatment of AUDs act either as a mu-opioid antagonist or a NMDA receptor modulator (e.g. naltrexone, acamprosate, respectively) (Yahn et al. 2013) . Based on our pre-clinical models, GLO1 inhibition reduces anxiety-like behavior and EtOH consumption by a mechanism that may be distinct from those currently in use.
In summary, the studies presented here suggest that manipulation of Glo1 can influence EtOH consumption, thus offering a novel target for the treatment of AUDs. Our previous studies have established a therapeutic potential for GLO1 inhibition in the treatment of anxiety disorders, which in conjunction with the data presented here, suggest GLO1 inhibition may be of particular interest for treatment of comorbid AUD and anxiety disorder.
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